MEMORIAL DAY FLASH SALE: 50% OFF BENZINGA PRO
As we honor our freedom, take a stand today. Secure the financial freedom that both you and your family deserve. Get exclusive market moving news for just 50% off. Claim your 50% discount here.
- Despite recent investor skepticism, the Phase 3 COVID-19 results for Veru Inc's (NASDAQ:VERU) sabizabulin published in the New England Journal of Medicine "addressed most concerns," Jefferies writes.
- The analyst sees the data as "further derisking" Veru's COVID opportunity and reiterates a Buy rating on the shares with a $55 price target.
- The data likely signals an FDA Emergency Use Authorization in 30 days, Howerton contends.
- Related: Veru Seeks FDA Emergency Use Nod For Its COVID-19 Treatment.
- Patients enrolled are, in fact, sicker and support the higher mortality observed.
- There was no meaningful impact of region on outcomes. The baseline demographics were well-balanced across arms, says the analyst.
- Sabizabulin treatment showed a statistically significant and clinically meaningful 55.2% reduction in deaths compared to placebo in moderate-severe hospitalized COVID-19 patients.
- The sabizabulin treatment had a significant and clinically meaningful reduction in days in ICU, mechanical ventilation, and the hospital.
- Sabizabulin was well tolerated with a more favorable safety profile compared to placebo.
- HC Wainwright notes that no current FDA-approved or authorized COVID-19 therapeutics in the hospital setting can achieve over 50% relative reduction in deaths.
- Hence, sabizabulin can potentially become the new standard of care for hospitalized moderate-severe COVID-19 patients if its EUA application is granted.
- Price Action: VERU shares are up 4.53% at $13.61 during the market session on the last check Thursday.
MEMORIAL DAY FLASH SALE: 50% OFF BENZINGA PRO
As we honor our freedom, take a stand today. Secure the financial freedom that both you and your family deserve. Get exclusive market moving news for just 50% off. Claim your 50% discount here.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!